Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 14
Submit an article Journal homepage
177
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance

Matthew Harwooda Gold Coast University Hospital, Southport, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7415-6708View further author information
ORCID Icon,
Georgina Hodgesb Townsville University Hospital, Townsville, AustraliaView further author information
,
Xuan Tanc Sir Charles Gairdner Hospital, Nedlands, Australia;d School of Medicine, University of Western Australia, Perth, AustraliaView further author information
,
Chan Y. Cheahc Sir Charles Gairdner Hospital, Nedlands, Australia;d School of Medicine, University of Western Australia, Perth, AustraliaView further author information
,
Kenneth Lime St Vincent’s Hospital Melbourne, Fitzroy, AustraliaORCID Iconhttps://orcid.org/0000-0002-2664-116XView further author information
ORCID Icon,
Matthew Kue St Vincent’s Hospital Melbourne, Fitzroy, Australia;f School of Medicine, University of Melbourne, Fitzroy, AustraliaView further author information
,
Constantine Tame St Vincent’s Hospital Melbourne, Fitzroy, AustraliaORCID Iconhttps://orcid.org/0000-0002-9759-5017View further author information
ORCID Icon,
Ingemar Lagerlofg Division of Experimental and Clinical Oncology, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SwedenView further author information
&
Tara Cochranea Gold Coast University Hospital, Southport, Australia;h School of Medicine, Griffith University, Southport, AustraliaView further author information
 show all
Pages 3412-3416 | Received 23 May 2020, Accepted 10 Aug 2020, Published online: 28 Aug 2020

References

  • Merli F, Luminari S, Gobbi PG, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016;34(11):1175–1181.
  • Viviani S, Zinzani PL, Rambaldi A, Intergruppo Italiano Linfomi, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011;365(3):203–212.
  • Skoetz N, Will A, Monsef I, et al. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2017;5:CD007941.
  • Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016;374(25):2419–2429.
  • Casasnovas RO, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20(2):202–215.
  • Borchmann P, Haverkamp H, Lohri A, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol. 2017;18(4):454–463.
  • Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
  • Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144–1153.
  • Wannesson L, Bargetzi M, Cairoli A, et al. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Leuk Lymphoma. 2013;54(1):36–40.
  • Zinzani PL, Ramachandren R, Santoro A, et al. Phase 3, randomized, open label study of Pembrolizumab versus Brentuximab Vedotin for treatment of relapsed or refractory classical Hodgkin lymphoma. KEYNOTE 204 European Haematology Association Meeting. 2020 Dec 6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.